Eisai Co., Ltd. (ESALY)
ValueMarkers Composite Index
DCF data not available
Eisai Co., Ltd. (ESALY) — VMCI valuation read
Eisai Co., Ltd. (ESALY) carries a VMCI composite of 64/100, 14 points above the Healthcare sector median of 50. Among mid-cap names, that gap places ESALY in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).
The ESALY insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.
**Investor frame.** Value reads ESALY trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 1.6x is the rate-sensitivity line to watch, the line to track on Eisai Co., Ltd.'s next 10-Q.
ESALY fell 2.8% over the trailing 7 days, with a -14.3% read on a 30-day basis.
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.